Subscribe for full access
Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Recommendation Rating
2
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 1.02
Low: 1.02
High: 1.02
Total Analysts: 1
Company Profile
BiVictriX Therapeutics plc is a United Kingdom-based drug discovery and development company focused on developing cancer therapeutics. The Company’s lead program, BVX001, is a Bi-Cygni antibody drug conjugate (ADC) designed to target the cancer-specific Bi-Cygni fingerprint, CD7 x CD33, found on the cancer cells of approximately 25-30% of patients with acute myeloid leukemia (AML), and in subpopulations of cancer cells from patients with other hematological cancers. The Company generates a pipeline of Bi-Cygni ADC therapeutics which are designed to selectively target cancer-specific antigen pairs, or Bi-Cygni fingerprints on tumor cells, which are largely absent from healthy cells. It has established a library of cancer-specific Bi-Cygni fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilizes these Bi-Cygni fingerprints, together with the Company’s ADC therapeutic design, to develop therapeutics to target cancers.
We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan.
